Author: admin

Author: admin

Xynomic Dosed First Patient in Phase 1/2 Lymphoma Trial
06/14/2019 Uncategorized admin

RALEIGH, N.C. and SHANGHAI, June 06, 2019 (GLOBE NEWSWIRE) —  Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, Nasdaq: XYN), a clinical stage US-China oncology drug development company, announced that Xynomic has dosed the first patient in a
Details

Xynomic Pharma To Present Long-Term Follow Up Data Showing Abexinostat, Combined with Pazopanib, has Durable Responses in Patients with Pre-Treated Kidney Cancer
Image 05/22/2019 Uncategorized admin

RALEIGH, N.C. and SHANGHAI, May 21, 2019 (GLOBE NEWSWIRE) — Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”), a clinical stage US-China oncology drug development company (XYN), announced today that long-term follow up data of exceptional responders to
Details

Xynomic Pharma 2019 ASCO Annual Meeting Abstracts
Image 05/16/2019 news admin

Xynomic Pharmaceuticals Holdings, Inc. (Nasdaq: XYN), a clinical stage US-China oncology drug development company, and its collaborators will present at the American Society of Clinical Oncology (“ASCO”) 2019 Annual Meeting to be held in Chicago from May 31, 2019 – June
Details

Mr. Y. Mark Xu, Chairman of Xynomic Pharma Participated in the “BioPharma Investment and Partnering in China” Panel Discussion Hosted by Bayer
Image 04/02/2019 news admin

On Thursday, March 28th, Bayer, ChinaBio and Shanghai Healthcare Drinks held a discussion panel entitled “BioPharma Investment and Partnering in China”. The event was hosted by Bayer at its Shanghai Pudong Office, where it brought
Details

Xynomic Pharmaceuticals, Inc. Will Present at ASCO 2019 Annual Meeting, Will Sponsor an EU Investigator Meeting for Potentially Pivotal Kidney Cancer Trial, and Appoints Interim Chief Accounting Officer
04/02/2019 Uncategorized admin

RALEIGH, N.C. and SHANGHAI, March 20, 2019 /PRNewswire/ — Xynomic Pharmaceuticals, Inc. (“Xynomic”), a clinical stage US-China oncology drug development company, and Bison Capital Acquisition Corporation (Nasdaq: BCAC), jointly announced that Xynomic and its collaborators will present at the American Society
Details

Xynomic Pharma Achieves Important Regulatory Milestones in China and EU in Potentially Pivotal Kidney Cancer and Lymphoma Trials
04/02/2019 Uncategorized admin

RALEIGH, N.C. and SHANGHAI, March 16, 2019 /PRNewswire/ — Xynomic Pharma, a clinical stage US-China oncology drug development company, and Bison Capital Acquisition Corp. (Nasdaq: BCAC), today jointly announced that China, Spain and Poland authorities have approved Xynomic’s application to conduct potentially pivotal Phase 3 trial
Details

Xynomic Pharma Doses First South Korean Patient in Phase 3 Renal Cell Carcinoma Trial and Hires Senior Executive Dr. Sophia Paspal to Head Regulatory Affairs and Quality Assurance
Image 02/25/2019 Uncategorized admin

RALEIGH, N.C. and SHANGHAI, Feb. 23, 2019 /PRNewswire/ — Xynomic Pharma, a clinical stage US-China oncology drug development company, and Bison Capital Acquisition Corp. (Nasdaq: BCAC), today jointly announced the dosing of the first South
Details

Xynomic Pharma Acquires Global Exclusive Rights to Phase 2 Ready mTORC1/2 Inhibitor from Boehringer Ingelheim
Image 12/23/2018 Uncategorized admin

  Dec 20, 2018, 10:52 ET DOVER, Del. and SHANGHAI, Dec. 20, 2018 /PRNewswire/ — Xynomic Pharmaceuticals, Inc. (“Xynomic”), a clinical stage US-China oncology drug development company, today announced that it has been granted an exclusive, worldwide license to
Details

Mr. Y. Mark Xu, Chairman of Xynomic Pharma Presented at the BioCentury China Healthcare Summit 2018
Image 11/19/2018 Uncategorized admin

China’s Globally Facing Future: How China’s healthcare pathfinders are leveraging the nation’s innovation, policy initiatives and access to capital markets in HK and domestic exchanges to build a globally facing industry. Five years ago, the first China
Details

Mr. Y. Mark Xu, Chairman of Xynomic Pharma, will provide an update of its innovative oncology drug pipeline at the BioCentury China Healthcare Summit 2018.
Image 11/07/2018 Uncategorized admin

Mr. Y. Mark Xu, Chairman of Xynomic Pharma, will provide an update of its innovative oncology drug pipeline at the BioCentury China Healthcare Summit 2018. Mr. Xu will present at 12:55 pm on Tuesday, November
Details